New UK ADR research centre set up
This article was originally published in Scrip
Four pharmaceutical companies and the UK Medical Research Councilare among the financial supporters of a new centre aimed at reducing the risks of adverse drug effects. The MRC Centre for Drug Safety Science will be based at the University of Liverpool's school of biomedical sciences and will provide training programmes for clinical and non-clinical drug safety scientists. It will be led by director Professor Kevin Park and will also involve researchers at Manchester University. The centre has received £3.7 million in funding from the MRC, and companies supporting the centre includeAstraZeneca, Novartis, PfizerandMerck & Co.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.